So much money has flowed into Moderna Therapeutics, it was only a matter of time before the company started spending real dough.
Cambridge, MA-based Moderna, which is developing a new class... Read more »
[Correction: 5:45 pm PT 1/14/14] Seattle-based Juno Therapeutics is already one of the richest biotech startups in industry history, and today it got even richer.
The company said today... Read more »
It’s just another day at the office for Moderna Therapeutics. Ho hum, it secured another $125 million.
The Cambridge, MA-based biotech company, which is seeking to create a new class... Read more »
Alkermes doesn’t want to be the little fish that ends up getting swallowed by a big fish someday, like so many other biotechs. Today it has raised another $250 million so... Read more »
Somebody always has to announce a monster acquisition, or gee-whiz biotech/pharma partnership, on the eve of the JP Morgan Healthcare Conference in San Francisco. Everyone wants to be the center of... Read more »
Ali Tehrani wants to prove that he didn’t just get lucky three years ago when his company, Vancouver, BC-based Zymeworks, struck a partnership with Merck. So today Zymeworks is announcing... Read more »
Seattle Genetics is best known for its one successful marketed cancer drug, but it has been busy working behind the scenes for years on new technologies for making souped-up antibodies against... Read more »
What has Josh Boger been doing the past four years in his supposed “retirement” from Vertex Pharmaceuticals?
Turns out, he’s found peace and beauty. He discovered it about as... Read more »
San Francisco, we’re coming. Of course, you are ready for the biotech onslaught. The cab drivers, hotel people, cops, security dudes, restaurant and bar staff—you all know the drill come January.... Read more »
One of the big stories on the leading edge of drug development is unfolding at a small biotech company few people have heard of on the west side of Madison, WI.... Read more »
Seattle-based IDRI just reflected a bit as it celebrated its 20th anniversary, and now it is getting a new business leader to take it ahead.
The nonprofit global health research center... Read more »
Four years ago, Exact Sciences was roadkill. The company, based in greater Boston at the time, had been experimenting with molecular diagnostic technologies for more than a dozen years. It had... Read more »
[Updated: 7:40 am PT 12/18/13] Seattle-based Acucela is looking to raise as much as $125 million in an initial public offering to support its development of treatments against eye... Read more »
The Bill & Melinda Gates Foundation just got a physician, big university administrator, and one of the world’s most respected drug developers rolled into one as its new CEO.
Susan Desmond-Hellmann,... Read more »
Amgen (NASDAQ: AMGN) tends to scoop up entrepreneurial teams and plug their work into the mother ship, not spin out cool ideas and entrepreneurs. But a couple of experimental drugs... Read more »
Every year, Science magazine profiles its “Breakthrough of the Year.” People get excited. But what many readers don’t fully appreciate is that these discoveries—at least in biomedicine—are almost always... Read more »
Why would anybody want to build a biotech company to last? Isn’t that old-school? Doesn’t it make more sense to run lean and mean, hit a technical milestone, then sell the... Read more »
Advances in the treatment of blood cancer were in the news this week. If you missed some of the signal while seeing a lot of noise from press releases, tweets, and... Read more »
The Xconomy team is getting ready to head over to Genentech Hall on the UCSF Mission Bay campus this afternoon for “Building Biotechs to Last.” Almost 200 people are... Read more »
Remember when Merck was the most admired company in America? When pharmaceutical companies ranked among the most respected of all industries, because of their achievements for human health and well-being?
I... Read more »